Posted by Michael Wonder on 28 Dec 2022
Calquence approved in Japan for adults with treatment naïve chronic lymphocytic leukaemia
28 December 2022 - Calquence significantly increased the time patients lived without disease progression or death versus chemoimmunotherapy.
AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (including small lymphocytic lymphoma).
Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia.
